Both companies may succeed in this industry.

NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded ...

Viking Therapeutics CEO Brian Lian said pharmaceutical companies are showing broader and deeper strategic interest in weight-loss drug deals than is immediately visible, as the global obesity ...

Despite a challenging year, the company has a lot to look forward to in the coming years.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best US stocks to buy under $50. On January 12, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced a significant milestone in the development of ...

We recently published 10 Big Names Delivering Outsized Gains. Viking Therapeutics Inc. (NASDAQ:VKTX) was one of the top ...

CINCINNATI, Aug. 5, 2025 /PRNewswire/ -- Viking Partners, a private real estate investment firm, closed on a $50.4 million acquisition of a 409,000-square-foot portfolio of small-bay industrial assets ...

Viking Therapeutics faces tough competition in the obesity drug market dominated by Eli Lilly and Novo Nordisk, with first-mover advantages hard to overcome. VK2735 shows promising early efficacy and ...

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...

Viking Revolution, the men's grooming brand known for their effective formulas, quality ingredients and affordable prices, today expanded into Walmart stores nationwide. Beginning today, consumers can ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...